Pam Belluck

Pam Belluck, a health and science writer for The New York Times, dives into the controversial approval of Aduhelm, the first Alzheimer’s treatment in nearly two decades. She reveals the conflicting opinions surrounding its efficacy and the emotional turmoil faced by families navigating Alzheimer’s care. The discussion covers the journey of clinical trial participants, the drug’s potential to alter the landscape of Alzheimer treatment, and the broader implications of hope amid uncertainty in medical choices.